NewsBenzingaDaré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance Benzinga 2026.10.02 20:05 (GMT+0) Open on Benzinga Other news UBS Maintains Buy on Keysight Techs, Lowers Price Target to $380 UBS Maintains Neutral on Intuit, Lowers Price Target to $315 Walmart Gets Bullish Rating Despite Pharmacy Deflation Headwinds Sky's USDC Exit Reserve Rises 29% to 1.13 Billion UBS Maintains Neutral on Ingredion, Lowers Price Target to $98 UBS Maintains Neutral on Hewlett Packard, Lowers Price Target to $52